cefroxadine and Cystitis

Cefroxadine (CXD) was administered to patients with acute uncomplicated cystitis (AUC) in a dose of 250 mg t.i.d. for 3-7 days. The patients were divided into 2 groups (less than 70 and greater than or equal to 70 years old) and clinical efficacy and incidents of recurrence were assessed. 1. Out of 83 patients treated, clinical efficacy was evaluated in 62 patients including 10 elder patients on the 3rd day and in 47 patients including 9 elder patients on the 7th day. In both groups clinical efficacy rates were 100% on the 3rd and 7th day. 2. Among 24 patients including 7 elder patients, who showed excellent response on the 7th day, recurrence was examined on the 14th day. The recurrence rate was 0% by the criteria proposed by the UTI committee in Japan. However, two patients (under 70 years of age) among them were considered as positive for recurrence by doctors in charge. Consequently, in both aged groups CXD showed excellent results in the treatment of AUC.

Topics: Acute Disease; Administration, Oral; Adult; Age Factors; Aged; Cephalosporins; Cephradine; Cystitis; Drug Evaluation; Female; Humans; Male; Middle Aged; Recurrence

CGP 9000 (cefroxadine), a new cephalosporine derived from N-acyl-3-alkoxy-7-amino-3-cefem-4-carboxylic acid for exclusively oral use, has been experimented on 67 patients, 41 adults and 20 children. CGP 9000 appeared to possess good therapeutic activity, even in low doses: its rapid absorption and moderate sero-protein bond are a guarantee of an immediate and almost total bioavailability.

Topics: Adolescent; Adult; Bacterial Infections; Biological Availability; Bronchitis; Bronchopneumonia; Cephalosporins; Cephradine; Child; Child, Preschool; Cystitis; Drug Evaluation; Erysipelas; Female; Humans; Infant; Male; Middle Aged; Mouth Diseases; Parotitis; Scarlet Fever